Barrow, Hanley, Mewhinney & Strauss
SPPI

Barrow, Hanley, Mewhinney & Strauss’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-231,745
Closed -$3.26M – 442
2017
Q3 		$3.26M Hold
231,745
– – ﹤0.01% 241
2017
Q2 		$1.73M Hold
231,745
– – ﹤0.01% 273
2017
Q1 		$1.51M Sell
231,745
-7,243
-3% -$40.5K ﹤0.01% 280
2016
Q4 		$1.06M Hold
238,988
– – ﹤0.01% 301
2016
Q3 		$1.12M Buy
+238,988
New +$1.42M ﹤0.01% 286

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's SPPI Position: Q4 2017 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q4 2017, closing a stake of 231,745 shares — an estimated $3.26M sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in SPPI in Q3 2016 and held it in 5 quarters. The position peaked at $3.26M in Q3 2017. 157 funds tracked by Wall St. Rank hold SPPI as of Q4 2017.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Spectrum Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 231,745 Spectrum Pharmaceuticals Inc shares in Q4 2017, an estimated $3.26M.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Spectrum Pharmaceuticals Inc in Q3 2016 and held it in 5 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Spectrum Pharmaceuticals Inc position peaked at $3.26M in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q4 2017.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q4 2017, filed 9 Feb 2018.